Tonix Pharmaceuticals Holding Corporation (TNXP) News

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for...

Form 8-K - Current report

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to...

Form 8-K - Current report

Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta

TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox...

Form 8-K - Current report

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek

Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress...